Table A5.
Association Between Week-1 Metabolic Response and Clinical Benefit by RECIST v1.0
| Week-1 Metabolic Response | Clinical Benefit No. (%) |
Total | Predictive Value |
||
|---|---|---|---|---|---|
| Yes | No | PPV (%) | NPV (%) | ||
| Cohort 1 | |||||
| PMR | 21 (75.0) | 7 (25.0) | 28 | 75 | 82 |
| SMD/PMD | 2 (18.2) | 9 (81.8) | 11 | ||
| Unknown | 0 (0.0) | 1 (100.0) | 1 | ||
| Total | 23 (57.5) | 17 (42.5) | 40 | ||
| Cohort 2 | |||||
| PMR | 12 (57.1) | 9 (42.9) | 21 | 57 | 77 |
| SMD | 5 (22.7) | 17 (77.3) | 22 | ||
| Unknown | 1 (50.0) | 1 (50.0) | 2 | ||
| Total | 18 (40.0) | 27 (60.0) | 45 | ||
NOTE. Patients were tabulated by clinical benefit (clinical benefit v no clinical benefit) and metabolic response (partial metabolic response [PMR] v stable metabolic disease [SMD]/progressive metabolic disease [PMD]). Clinical benefit was defined as confirmed complete response plus confirmed partial response plus stable disease ≥ 24 weeks. Patients with unconfirmed complete response, unconfirmed partial response, stable disease < 24 weeks, and progressive disease as best response were considered nonresponders for this analysis. Metabolic response was based on European Organisation for Research and Treatment of Cancer criteria.
Abbreviations: NPV, negative predictive value; PPV, positive predictive value.